Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
Anoop Prakash,1 K Suresh Babu,2 Jaymin B Morjaria1,31Department of Respiratory Medicine, Castle Hill Hospital, Cottingham, 2Department of Respiratory Medicine, Queen Alexandra Hospital, Cosham, Portsmouth, 3Department of Academic Respiratory Medicine, Hull York Medical School, University of Hull, Ca...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-01-01
|
| Series: | International Journal of COPD |
| Online Access: | http://www.dovepress.com/profile-of-inhaled-glycopyrronium-bromide-as-monotherapy-and-in-fixed--peer-reviewed-article-COPD |
| _version_ | 1819178865431412736 |
|---|---|
| author | Prakash A Babu KS Morjaria JB |
| author_facet | Prakash A Babu KS Morjaria JB |
| author_sort | Prakash A |
| collection | DOAJ |
| description | Anoop Prakash,1 K Suresh Babu,2 Jaymin B Morjaria1,31Department of Respiratory Medicine, Castle Hill Hospital, Cottingham, 2Department of Respiratory Medicine, Queen Alexandra Hospital, Cosham, Portsmouth, 3Department of Academic Respiratory Medicine, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, UKAbstract: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. The cornerstone of pharmacological treatment for COPD is bronchodilation. Inhaled glycopyrronium bromide is a long-acting muscarinic antagonist developed as a maintenance treatment for patients with COPD. Phase III trials have shown that glycopyrronium produces rapid and sustained bronchodilation with an efficacy similar to tiotropium and is well tolerated, with a low incidence of muscarinic side effects in patients with moderate to severe COPD. A combination of glycopyrronium bromide with indacaterol maleate (QVA149) has recently been approved as a once-daily maintenance therapy in adult patients with COPD. Phase III trials (the IGNITE program) with QVA149 have demonstrated significant improvements in lung function versus placebo, glycopyrronium, and tiotropium in patients with moderate to severe COPD, with no safety concerns of note. Hence QVA149 is a safe treatment option for moderate to severe COPD patients in whom long-acting muscarinic antagonist monotherapy is inadequate.Keywords: chronic obstructive pulmonary disease, glycopyrronium bromide, indacaterol maleate, umeclidinium, QVA149, long-acting muscarinic antagonist |
| first_indexed | 2024-12-22T21:49:20Z |
| format | Article |
| id | doaj.art-b30f397a86284c22836e7b652f299f77 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-22T21:49:20Z |
| publishDate | 2015-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-b30f397a86284c22836e7b652f299f772022-12-21T18:11:24ZengDove Medical PressInternational Journal of COPD1178-20052015-01-012015default11112319859Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPDPrakash ABabu KSMorjaria JBAnoop Prakash,1 K Suresh Babu,2 Jaymin B Morjaria1,31Department of Respiratory Medicine, Castle Hill Hospital, Cottingham, 2Department of Respiratory Medicine, Queen Alexandra Hospital, Cosham, Portsmouth, 3Department of Academic Respiratory Medicine, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, UKAbstract: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. The cornerstone of pharmacological treatment for COPD is bronchodilation. Inhaled glycopyrronium bromide is a long-acting muscarinic antagonist developed as a maintenance treatment for patients with COPD. Phase III trials have shown that glycopyrronium produces rapid and sustained bronchodilation with an efficacy similar to tiotropium and is well tolerated, with a low incidence of muscarinic side effects in patients with moderate to severe COPD. A combination of glycopyrronium bromide with indacaterol maleate (QVA149) has recently been approved as a once-daily maintenance therapy in adult patients with COPD. Phase III trials (the IGNITE program) with QVA149 have demonstrated significant improvements in lung function versus placebo, glycopyrronium, and tiotropium in patients with moderate to severe COPD, with no safety concerns of note. Hence QVA149 is a safe treatment option for moderate to severe COPD patients in whom long-acting muscarinic antagonist monotherapy is inadequate.Keywords: chronic obstructive pulmonary disease, glycopyrronium bromide, indacaterol maleate, umeclidinium, QVA149, long-acting muscarinic antagonisthttp://www.dovepress.com/profile-of-inhaled-glycopyrronium-bromide-as-monotherapy-and-in-fixed--peer-reviewed-article-COPD |
| spellingShingle | Prakash A Babu KS Morjaria JB Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD International Journal of COPD |
| title | Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD |
| title_full | Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD |
| title_fullStr | Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD |
| title_full_unstemmed | Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD |
| title_short | Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD |
| title_sort | profile of inhaled glycopyrronium bromide as monotherapy and in fixed dose combination with indacaterol maleate for the treatment of copd |
| url | http://www.dovepress.com/profile-of-inhaled-glycopyrronium-bromide-as-monotherapy-and-in-fixed--peer-reviewed-article-COPD |
| work_keys_str_mv | AT prakasha profileofinhaledglycopyrroniumbromideasmonotherapyandinfixeddosecombinationwithindacaterolmaleateforthetreatmentofcopd AT babuks profileofinhaledglycopyrroniumbromideasmonotherapyandinfixeddosecombinationwithindacaterolmaleateforthetreatmentofcopd AT morjariajb profileofinhaledglycopyrroniumbromideasmonotherapyandinfixeddosecombinationwithindacaterolmaleateforthetreatmentofcopd |